Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2021 Gastrointestinal Cancers Symposium
2020 San Antonio Breast Cancer Symposium
2020 ASH Annual Meeting & Exposition
ESMO Immuno-Oncology Virtual Congress 2020
ESMO Asia Virtual Congress 2020
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Roundtable:
Lymphoma/Myeloma
Roundtable:
Lung Cancer
Podcasts
CME
Methotrexate–Induced Kidney Injury
Advertisement
Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority
First International Summit on Interventional Pharmacoeconomics
Advertisement
Related Videos
CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country
Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib
David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease
Welcome and Introduction to Vi3C
Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept
Advertisement
Advertisement
Jan
21
Today In Oncology
Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy
Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC
Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer
View More
Advertisement